Intech Investment Management LLC Takes $268,000 Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Intech Investment Management LLC bought a new position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 24,761 shares of the company’s stock, valued at approximately $268,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of 4D Molecular Therapeutics during the 3rd quarter worth about $295,000. Privium Fund Management B.V. raised its position in 4D Molecular Therapeutics by 146.3% in the 3rd quarter. Privium Fund Management B.V. now owns 98,500 shares of the company’s stock valued at $1,065,000 after purchasing an additional 58,500 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in 4D Molecular Therapeutics during the 3rd quarter worth about $108,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of 4D Molecular Therapeutics by 64.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock valued at $108,000 after purchasing an additional 3,922 shares in the last quarter. Finally, Novo Holdings A S boosted its position in 4D Molecular Therapeutics by 7.1% in the 3rd quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock valued at $16,215,000 after buying an additional 100,000 shares during the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Performance

FDMT opened at $6.82 on Friday. The firm has a market capitalization of $315.27 million, a PE ratio of -2.39 and a beta of 2.74. 4D Molecular Therapeutics, Inc. has a 52-week low of $6.78 and a 52-week high of $36.25. The business’s 50-day simple moving average is $8.58 and its 200 day simple moving average is $15.44.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on FDMT shares. Morgan Stanley initiated coverage on shares of 4D Molecular Therapeutics in a research note on Thursday, November 21st. They issued an “underweight” rating and a $8.00 price objective on the stock. Royal Bank of Canada reduced their price objective on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Cantor Fitzgerald lowered shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, September 23rd. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $39.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $42.13.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.